TORONTO--(BW HealthWire)--Feb. 5, 2002--MDS Proteomics Inc. (NYSE:MDZ - news; TSE:MDS - news) today announced that they have acquired a collection of nearly 2,000 disease related, full-length complementary DNA (cDNA) clones, providing the raw material for proteomics-based drug discovery research. The three-year deal with Japan's Kazusa DNA Research Institute, a leading supplier of high quality cDNA, provides MDS Proteomics with access to one of the richest cDNA collections in the world.
``This partnership with Kazusa is a major step in enabling MDS Proteomics to meet our goal of discovering 1,000 new drug targets in the next five years by mapping human disease pathways,'' said Frank Gleeson, president and chief executive officer, MDS Proteomics. ``Access to Kazusa's collection of cDNA is essential to creating focused maps of important human diseases -- ultimately leading to the faster development of safer, more targeted medicines.''
cDNAs are key reagents for proteomics-based research. MDS Proteomics will use Kazusa's disease related clones as entry points or ``genetic baits'' in its automated process for rapidly mapping disease pathways and determining protein function and cell regulation. By creating maps of disease states such as breast cancer, the company can precisely locate disease-associated proteins for treatment with more specific and effective drugs... |
